Following up on the January approval of Vertex Pharmaceuticals Inc.’s Kalydeco (ivacaftor), the first drug to address the underlying cause of cystic fibrosis, Pfizer Inc. and the Cystic Fibrosis Foundation are teaming up in a $58 million extension of an existing R&D alliance to bring additional root-cause-focused drugs into clinical development.
Maryland-based CFF is partnered with multiple companies, including Vertex and Genzyme Corp., to help fund CF drug development. In an interview, CFF President and CEO Robert Beall said the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?